The use of SGLT2 inhibitors was not associated with a clear increase in overall UTI risk among patients with RA and diabetes.
Although both sodium-glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) ...
Panelists discuss how SGLT2 inhibitors evolved from diabetes medications to become foundational heart failure therapy with class I recommendations across the ejection fraction spectrum, providing ...
SGLT2 inhibitors may help reduce the risk of nephrolithiasis in patients with type 2 diabetes, including those with co-existing gout. Recent large-scale studies support that sodium-glucose ...
Researchers in Germany conducted a retrospective cohort study to assess whether SGLT2 inhibitor use is linked to a lower incidence of iron deficiency anaemia in patients with T2D. They analysed 28,441 ...
Once-daily, oral SGLT2 inhibitor shown to reduce blood sugar and improve glycemic control as an adjunct to diet and exercise MARLBOROUGH, Mass.--(BUSINESS WIRE)--TheracosBio today announced that the U ...
CHICAGO -- Dapagliflozin (Farxiga) lowered mortality and heart failure worsening in high-risk older adults getting transcatheter aortic valve implantation (TAVI), the DapaTAVI trial showed. In a ...
When used in everyday practice, sodium-glucose cotransporter 2 (SGLT2) inhibitors provide rapid and sustained benefits to patients with a recent heart failure (HF) hospitalization, a nationwide ...
Preoperative SGLT2 inhibitor use was not associated with an increased risk for postoperative diabetic ketoacidosis among patients with type 2 diabetes. Use of sodium-glucose cotransporter 2 inhibitor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results